心力衰竭治疗的最新进展
该综述指出,射血分数降低的心力衰竭患者生存率已改善,新疗法首次显示可在整个射血分数谱系改善结局;心脏淀粉样变性和肥厚型心肌病等特定心肌病已可通过新型遗传与分子方法有效管理。但实施差距、疾病认知不足及社会经济决定因素仍限制试验成果转化,正在进行的试验、表型分型和技术的进步带来希望。
要点
- 射血分数降低的心力衰竭患者生存率已改善。
- 新疗法首次显示可在整个射血分数谱系改善结局。
- 心脏淀粉样变性和肥厚型心肌病等已可通过新型遗传与分子方法有效管理。
核心结论
- 心力衰竭治疗取得显著进展,但实施差距、疾病认知不足及社会经济决定因素仍限制成功试验转化为患者结局改善。
研究设计与样本
- 综述,未报告系统检索范围。
主要发现
- 射血分数降低的心力衰竭患者生存率已改善。
- 新疗法首次显示可在整个射血分数谱系改善结局。
- 心脏淀粉样变性和肥厚型心肌病等特定心肌病已可通过新型遗传与分子方法有效管理。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出将成功临床试验转化为患者结局改善受限于实施照护方面的巨大差距、疾病认知的广泛缺乏以及对结局的社会经济决定因素和如何解决差异理解不足。
- 原文指出心力衰竭仍存在大量未满足需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Remarkable recent advances have revolutionized the field of heart failure. Survival has improved among individuals with heart failure and a reduced ejection fraction and for the first time, new therapies have been shown to improve outcomes across the entire ejection fraction spectrum of heart failure. Great strides have been taken in the treatment of specific cardiomyopathies such as cardiac amyloidosis and hypertrophic cardiomyopathy, whereby conditions once considered incurable can now be effectively managed with novel genetic and molecular approaches. Yet there remain substantial residual unmet needs in heart failure. The translation of successful clinical trials to improved patient outcomes is limited by large gaps in implementation of care, widespread lack of disease awareness and poor understanding of the socioeconomic determinants of outcomes and how to address disparities. Ongoing clinical trials, advances in phenotype segmentation for precision medicine and the rise in technology solutions all offer hope for the future.
引用
- Lam CSP, Docherty KF, Ho JE, et al. Recent successes in heart failure treatment. Nat Med. 2023. PMID: 37814060. doi:10.1038/s41591-023-02567-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。